Arvinas, Inc. (NASDAQ:ARVN) Stock Holdings Boosted by Monaco Asset Management SAM

Key Points

• Monaco Asset Management SAM increased its stake in Arvinas, Inc. by 1,161.8% in the first quarter, owning 315,459 shares valued at approximately $2.22 million.
• A significant number of institutional investors, including XTX Topco Ltd and Federated Hermes Inc., have also raised their stakes in Arvinas, indicating a growing interest in the company.
• Research analysts have lowered their price targets on Arvinas shares, with a consensus target price of $20.29 and a rating of "Moderate Buy."

Monaco Asset Management SAM increased its holdings in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 1,161.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 315,459 shares of the company's stock after buying an additional 290,459 shares during the period. Arvinas accounts for about 0.5% of Monaco Asset Management SAM's investment portfolio, making the stock its 23rd biggest holding. Monaco Asset Management SAM owned approximately 0.43% of Arvinas worth $2,215,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. GF Fund Management CO. LTD. acquired a new stake in Arvinas in the fourth quarter valued at $28,000. GAMMA Investing LLC raised its position in shares of Arvinas by 11,283.8% in the 1st quarter. GAMMA Investing LLC now owns 4,212 shares of the company's stock valued at $300,000 after buying an additional 4,175 shares in the last quarter. CWM LLC grew its holdings in shares of Arvinas by 2,317.5% during the 1st quarter. CWM LLC now owns 7,615 shares of the company's stock valued at $53,000 after purchasing an additional 7,300 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of Arvinas during the 4th quarter valued at approximately $171,000. Finally, Allspring Global Investments Holdings LLC bought a new stake in Arvinas during the 1st quarter worth approximately $80,000. Institutional investors own 95.19% of the company's stock.

Insider Buying and Selling

In other Arvinas news, CFO Andrew Saik sold 5,700 shares of the business's stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $7.61, for a total transaction of $43,377.00. Following the completion of the sale, the chief financial officer owned 164,401 shares of the company's stock, valued at approximately $1,251,091.61. The trade was a 3.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.73% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Morgan Stanley reduced their price objective on shares of Arvinas from $12.00 to $11.00 and set an "equal weight" rating on the stock in a research note on Friday, May 9th. HC Wainwright set a $24.00 price objective on shares of Arvinas in a report on Monday, June 2nd. The Goldman Sachs Group lowered their target price on shares of Arvinas from $12.00 to $8.00 and set a "neutral" rating for the company in a report on Friday, May 2nd. Leerink Partners restated a "market perform" rating and set a $9.00 price objective (down previously from $10.00) on shares of Arvinas in a report on Monday, June 2nd. Finally, Barclays decreased their price objective on shares of Arvinas from $32.00 to $16.00 and set an "overweight" rating for the company in a report on Friday, May 2nd. Ten analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $20.29.

Arvinas Price Performance

Shares of ARVN stock traded down $0.02 during midday trading on Friday, hitting $7.42. The company had a trading volume of 1,465,745 shares, compared to its average volume of 1,842,942. The company's 50 day simple moving average is $7.55 and its 200 day simple moving average is $10.35. Arvinas, Inc. has a 52-week low of $5.90 and a 52-week high of $29.61. The stock has a market cap of $541.59 million, a price-to-earnings ratio of -11.24 and a beta of 2.22.

Arvinas (NASDAQ:ARVN - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported $1.14 EPS for the quarter, topping analysts' consensus estimates of ($0.93) by $2.07. Arvinas had a negative return on equity of 7.74% and a negative net margin of 10.92%. During the same quarter in the prior year, the business earned ($0.97) EPS. The business's revenue for the quarter was up 646.2% compared to the same quarter last year. Analysts anticipate that Arvinas, Inc. will post -3.81 EPS for the current year.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.